loading
Schlusskurs vom Vortag:
$7.10
Offen:
$7.12
24-Stunden-Volumen:
378.85K
Relative Volume:
0.61
Marktkapitalisierung:
$380.55M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.462
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-10.08%
1M Leistung:
+0.79%
6M Leistung:
+72.37%
1J Leistung:
-18.02%
1-Tages-Spanne:
Value
$6.975
$7.31
1-Wochen-Bereich:
Value
$6.975
$8.10
52-Wochen-Spanne:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Firmenname
Fulcrum Therapeutics Inc
Name
Telefon
617-651-8851
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
45
Name
Twitter
@fulcrumtx
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
FULC's Discussions on Twitter

Vergleichen Sie FULC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
7.05 423.20M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-23 Hochstufung Leerink Partners Market Perform → Outperform
2025-05-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-09-13 Herabstufung H.C. Wainwright Buy → Neutral
2024-09-12 Herabstufung BofA Securities Neutral → Underperform
2024-09-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-09-12 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Herabstufung Stifel Buy → Hold
2024-09-09 Hochstufung BofA Securities Underperform → Neutral
2024-05-20 Eingeleitet Cantor Fitzgerald Overweight
2024-03-13 Eingeleitet RBC Capital Mkts Outperform
2023-09-25 Eingeleitet Goldman Neutral
2023-08-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-08-22 Hochstufung Stifel Hold → Buy
2023-05-04 Herabstufung Goldman Buy → Neutral
2023-03-10 Herabstufung Credit Suisse Outperform → Neutral
2023-03-10 Herabstufung H.C. Wainwright Buy → Neutral
2023-03-09 Herabstufung Stifel Buy → Hold
2023-02-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-02-24 Herabstufung BofA Securities Neutral → Underperform
2022-11-15 Eingeleitet Goldman Buy
2022-03-08 Eingeleitet Oppenheimer Outperform
2022-03-03 Hochstufung BofA Securities Underperform → Neutral
2021-08-11 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-02 Eingeleitet Stifel Buy
2020-10-16 Eingeleitet Piper Sandler Overweight
2020-08-12 Herabstufung BofA Securities Neutral → Underperform
2020-08-12 Bestätigt H.C. Wainwright Buy
2020-08-12 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-19 Herabstufung BofA/Merrill Buy → Neutral
2020-06-17 Eingeleitet BTIG Research Buy
2019-10-03 Eingeleitet H.C. Wainwright Buy
2019-08-12 Eingeleitet BofA/Merrill Buy
Alle ansehen

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Fulcrum Therapeutics Inc. stock priceOutstanding yields - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Fulcrum Therapeutics Inc. stockOutstanding risk-reward balance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Fulcrum Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Fulcrum Therapeutics Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

why fulcrum therapeutics inc. stock attracts strong analyst attentionWeekly Double Return List - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Fulcrum Therapeutics Inc. stock price move sharplyMarket Ready Callouts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Fulcrum Therapeutics Inc. stock performs during market volatilitySafe High Return Entry Points - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Fulcrum Therapeutics (FULC) Drops 2.25% Despite 3.25% Intraday Gain - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 11, 2025
pulisher
Jul 11, 2025

Fulcrum Therapeutics Awards Major Stock Options Package Worth $912,600 to Strategic New Hire - Stock Titan

Jul 11, 2025
pulisher
Jul 09, 2025

Fulcrum Therapeutics (FULC) Soars 14.31% on Earnings Report - AInvest

Jul 09, 2025
pulisher
Jun 28, 2025

Fulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years ago - Yahoo Finance

Jun 28, 2025
pulisher
Jun 27, 2025

Fulcrum Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 27, 2025
pulisher
Jun 25, 2025

Is Fulcrum Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 21, 2025

Cantor Fitzgerald Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail

Jun 21, 2025
pulisher
Jun 12, 2025

Bank of America Corp DE Has $432,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Research Analysts Issue Forecasts for FULC FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLC - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Fulcrum Therapeutics Awards Major Stock Options Package: 70,000 Shares at $6.96 Exercise Price - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jun 05, 2025
pulisher
May 30, 2025

Fulcrum Therapeutics (NASDAQ:FULC) shareholders are up 16% this past week, but still in the red over the last five years - simplywall.st

May 30, 2025

Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):